FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2757304856> ?p ?o ?g. }

• W2757304856 endingPage "2450" @default.
• W2757304856 startingPage "2440" @default.
• W2757304856 abstract "Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization.Patients who experienced acute coronary syndrome were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median of 6 years. Treatment efficacy was assessed for the entire population and by subgroups for the first and total (first and subsequent) events for the end points of stroke of any etiology, stroke subtypes, and the primary trial end point at 7 years.Of 18 144 patients, 641 (3.5%) experienced at least 1 stroke; most were ischemic (527, 82%). Independent predictors of stroke included prior stroke, older age, atrial fibrillation, congestive heart failure, diabetes mellitus, myocardial infarction, and renal dysfunction. There was a nonsignificant reduction in the first event of stroke of any etiology (4.2% versus 4.8%; hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.73-1.00; P=0.052) with ezetimibe/simvastatin versus placebo/simvastatin, driven by a significant 21% reduction in ischemic stroke (3.4% versus 4.1%; HR, 0.79; 95% CI, 0.67-0.94; P=0.008) and a nonsignificant increase in hemorrhagic stroke (0.8% versus 0.6%; HR, 1.38; 95% CI, 0.93-2.04; P=0.11). Evaluating total events, including the first and all recurrent strokes, ezetimibe/simvastatin reduced stroke of any etiology (HR, 0.83; 95% CI, 0.70-0.98; P=0.029) and ischemic stroke (HR, 0.76; 95% CI, 0.63-0.91; P=0.003). Patients who had experienced a stroke prior to randomization were at a higher risk of recurrence and demonstrated an absolute risk reduction of 8.6% for stroke of any etiology (10.2% versus 18.8%; number needed to treat=12; HR, 0.60; 95% CI, 0.38-0.95; P=0.030) and 7.6% for ischemic stroke (8.7% versus 16.3%; number needed to treat=13; HR, 0.52; 95% CI, 0.31-0.86; P=0.011) with ezetimibe added to simvastatin therapy.The addition of ezetimibe to simvastatin in patients stabilized after acute coronary syndrome reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke.URL: https://www.clinicaltrials.gov. Unique identifier: NCT00202878." @default.
• W2757304856 created "2017-10-06" @default.
• W2757304856 creator A5006743818 @default.
• W2757304856 creator A5016236841 @default.
• W2757304856 creator A5017802973 @default.
• W2757304856 creator A5020677154 @default.
• W2757304856 creator A5022267024 @default.
• W2757304856 creator A5026602252 @default.
• W2757304856 creator A5045665978 @default.
• W2757304856 creator A5062843291 @default.
• W2757304856 creator A5064339118 @default.
• W2757304856 creator A5082493414 @default.
• W2757304856 creator A5085573148 @default.
• W2757304856 creator A5085897222 @default.
• W2757304856 creator A5090147492 @default.
• W2757304856 creator A5090460841 @default.
• W2757304856 date "2017-12-19" @default.
• W2757304856 modified "2023-10-06" @default.
• W2757304856 title "Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)" @default.
• W2757304856 cites W1520609538 @default.
• W2757304856 cites W1546258268 @default.
• W2757304856 cites W1992798646 @default.
• W2757304856 cites W2002003793 @default.
• W2757304856 cites W2002189205 @default.
• W2757304856 cites W2014561045 @default.
• W2757304856 cites W2052094004 @default.
• W2757304856 cites W2121581403 @default.
• W2757304856 cites W2123639852 @default.
• W2757304856 cites W2124601103 @default.
• W2757304856 cites W2150799450 @default.
• W2757304856 cites W2151969933 @default.
• W2757304856 cites W2157372252 @default.
• W2757304856 cites W2162586165 @default.
• W2757304856 cites W2164089346 @default.
• W2757304856 cites W2196906371 @default.
• W2757304856 cites W2251889296 @default.
• W2757304856 cites W2465758073 @default.
• W2757304856 cites W2523307560 @default.
• W2757304856 cites W2596179513 @default.
• W2757304856 cites W2596236174 @default.
• W2757304856 cites W2605085471 @default.
• W2757304856 cites W4241543174 @default.
• W2757304856 doi "https://doi.org/10.1161/circulationaha.117.029095" @default.
• W2757304856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28972004" @default.
• W2757304856 hasPublicationYear "2017" @default.
• W2757304856 type Work @default.
• W2757304856 sameAs 2757304856 @default.
• W2757304856 citedByCount "96" @default.
• W2757304856 countsByYear W27573048562018 @default.
• W2757304856 countsByYear W27573048562019 @default.
• W2757304856 countsByYear W27573048562020 @default.
• W2757304856 countsByYear W27573048562021 @default.
• W2757304856 countsByYear W27573048562022 @default.
• W2757304856 countsByYear W27573048562023 @default.
• W2757304856 crossrefType "journal-article" @default.
• W2757304856 hasAuthorship W2757304856A5006743818 @default.
• W2757304856 hasAuthorship W2757304856A5016236841 @default.
• W2757304856 hasAuthorship W2757304856A5017802973 @default.
• W2757304856 hasAuthorship W2757304856A5020677154 @default.
• W2757304856 hasAuthorship W2757304856A5022267024 @default.
• W2757304856 hasAuthorship W2757304856A5026602252 @default.
• W2757304856 hasAuthorship W2757304856A5045665978 @default.
• W2757304856 hasAuthorship W2757304856A5062843291 @default.
• W2757304856 hasAuthorship W2757304856A5064339118 @default.
• W2757304856 hasAuthorship W2757304856A5082493414 @default.
• W2757304856 hasAuthorship W2757304856A5085573148 @default.
• W2757304856 hasAuthorship W2757304856A5085897222 @default.
• W2757304856 hasAuthorship W2757304856A5090147492 @default.
• W2757304856 hasAuthorship W2757304856A5090460841 @default.
• W2757304856 hasBestOaLocation W27573048561 @default.
• W2757304856 hasConcept C126322002 @default.
• W2757304856 hasConcept C127413603 @default.
• W2757304856 hasConcept C142724271 @default.
• W2757304856 hasConcept C164705383 @default.
• W2757304856 hasConcept C204787440 @default.
• W2757304856 hasConcept C207103383 @default.
• W2757304856 hasConcept C27081682 @default.
• W2757304856 hasConcept C2776329913 @default.
• W2757304856 hasConcept C2776839432 @default.
• W2757304856 hasConcept C2777698277 @default.
• W2757304856 hasConcept C2778198053 @default.
• W2757304856 hasConcept C2778657065 @default.
• W2757304856 hasConcept C2779161974 @default.
• W2757304856 hasConcept C2780645631 @default.
• W2757304856 hasConcept C2908647359 @default.
• W2757304856 hasConcept C44249647 @default.
• W2757304856 hasConcept C500558357 @default.
• W2757304856 hasConcept C71924100 @default.
• W2757304856 hasConcept C78519656 @default.
• W2757304856 hasConcept C99454951 @default.
• W2757304856 hasConceptScore W2757304856C126322002 @default.
• W2757304856 hasConceptScore W2757304856C127413603 @default.
• W2757304856 hasConceptScore W2757304856C142724271 @default.
• W2757304856 hasConceptScore W2757304856C164705383 @default.
• W2757304856 hasConceptScore W2757304856C204787440 @default.
• W2757304856 hasConceptScore W2757304856C207103383 @default.
• W2757304856 hasConceptScore W2757304856C27081682 @default.
• W2757304856 hasConceptScore W2757304856C2776329913 @default.

• next